Chugai seeks Japan approval for Enspryng to prevent MOGAD relapses
Chugai posts transcript of FY2026 Q2 financial results conference call
Chugai Pharmaceutical (TSE:4519) Stock Net Margin Strength Challenges Cost Pressure Concerns
Chugai Pharmaceutical reports 1H results
Chugai forecasts FY2026 dividend per share at JPY 132
Chugai Pharma FY26 Q2 net income climbs 19.2% to ¥231.7 billion; revenue rises 14.7% to ¥663.3 billion